Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer
Abstract Immunotherapy has revolutionized the treatment of gastrointestinal (GI) cancers, but reliable biomarkers for predicting treatment efficacy remain limited. In this study, we explored the potential of blood microbiome and specific microbial taxa as novel biomarkers for predicting the efficacy...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70316 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341672235728896 |
|---|---|
| author | Ya‐Shang Zheng Wu‐Hao Lin Jun‐Quan Chen Xiao‐Li Wei Jia‐Qian Huang Yu‐Hong Xu Meng Yang Qi‐Hua Zhang Zhi‐Jun Zuo Zhao‐Ying Yang Pan Zhang Nga Ki HONG Lu‐Xuan Liu Zhao‐Lei Zeng Rui‐Hua Xu Hui‐Yan Luo |
| author_facet | Ya‐Shang Zheng Wu‐Hao Lin Jun‐Quan Chen Xiao‐Li Wei Jia‐Qian Huang Yu‐Hong Xu Meng Yang Qi‐Hua Zhang Zhi‐Jun Zuo Zhao‐Ying Yang Pan Zhang Nga Ki HONG Lu‐Xuan Liu Zhao‐Lei Zeng Rui‐Hua Xu Hui‐Yan Luo |
| author_sort | Ya‐Shang Zheng |
| collection | DOAJ |
| description | Abstract Immunotherapy has revolutionized the treatment of gastrointestinal (GI) cancers, but reliable biomarkers for predicting treatment efficacy remain limited. In this study, we explored the potential of blood microbiome and specific microbial taxa as novel biomarkers for predicting the efficacy of immunotherapy combined with chemotherapy in GI cancer patients through 16S rRNA sequencing. Our findings demonstrated that lower baseline alpha diversity and specific microbial compositions, particularly lower levels of Lactobacillus, were significantly associated with longer progression‐free survival (PFS) in patients receiving immunotherapy combined with chemotherapy. Furthermore, we validated the reliability of Lactobacillus abundance as a predictor of PFS and treatment response in another independent patient cohort. Additionally, patients with increased or stable levels of Lactobacillus after immunotherapy combined with chemotherapy had superior PFS. Gavage of Lactobacillus rhamnosus (L. rhamnosus) el evated its blood level and enhanced the efficacy of immunotherapy in mouse models. Our results suggest that Lactobacillus may serve as a novel biomarker for predicting the efficacy of immunotherapy combined with chemotherapy and hold the potential as a PD‐1 antibody sensitizer. |
| format | Article |
| id | doaj-art-9f06e89e7a754a7cb5fbc2ea6d7396be |
| institution | Kabale University |
| issn | 2688-2663 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj-art-9f06e89e7a754a7cb5fbc2ea6d7396be2025-08-20T03:43:34ZengWileyMedComm2688-26632025-08-0168n/an/a10.1002/mco2.70316Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal CancerYa‐Shang Zheng0Wu‐Hao Lin1Jun‐Quan Chen2Xiao‐Li Wei3Jia‐Qian Huang4Yu‐Hong Xu5Meng Yang6Qi‐Hua Zhang7Zhi‐Jun Zuo8Zhao‐Ying Yang9Pan Zhang10Nga Ki HONG11Lu‐Xuan Liu12Zhao‐Lei Zeng13Rui‐Hua Xu14Hui‐Yan Luo15Department of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Molecular Diagnostics State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Anesthesiology Sun Yat‐Sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaSun Yat‐Sen University Zhongshan School of Medicine Guangzhou People's Republic of ChinaSun Yat‐Sen University Zhongshan School of Medicine Guangzhou People's Republic of ChinaSun Yat‐Sen University Zhongshan School of Medicine Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaDepartment of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐Sen University Cancer Center Guangzhou People's Republic of ChinaAbstract Immunotherapy has revolutionized the treatment of gastrointestinal (GI) cancers, but reliable biomarkers for predicting treatment efficacy remain limited. In this study, we explored the potential of blood microbiome and specific microbial taxa as novel biomarkers for predicting the efficacy of immunotherapy combined with chemotherapy in GI cancer patients through 16S rRNA sequencing. Our findings demonstrated that lower baseline alpha diversity and specific microbial compositions, particularly lower levels of Lactobacillus, were significantly associated with longer progression‐free survival (PFS) in patients receiving immunotherapy combined with chemotherapy. Furthermore, we validated the reliability of Lactobacillus abundance as a predictor of PFS and treatment response in another independent patient cohort. Additionally, patients with increased or stable levels of Lactobacillus after immunotherapy combined with chemotherapy had superior PFS. Gavage of Lactobacillus rhamnosus (L. rhamnosus) el evated its blood level and enhanced the efficacy of immunotherapy in mouse models. Our results suggest that Lactobacillus may serve as a novel biomarker for predicting the efficacy of immunotherapy combined with chemotherapy and hold the potential as a PD‐1 antibody sensitizer.https://doi.org/10.1002/mco2.70316biomarkerblood microbiomeefficacyimmunotherapyLactobacillus |
| spellingShingle | Ya‐Shang Zheng Wu‐Hao Lin Jun‐Quan Chen Xiao‐Li Wei Jia‐Qian Huang Yu‐Hong Xu Meng Yang Qi‐Hua Zhang Zhi‐Jun Zuo Zhao‐Ying Yang Pan Zhang Nga Ki HONG Lu‐Xuan Liu Zhao‐Lei Zeng Rui‐Hua Xu Hui‐Yan Luo Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer MedComm biomarker blood microbiome efficacy immunotherapy Lactobacillus |
| title | Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer |
| title_full | Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer |
| title_fullStr | Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer |
| title_full_unstemmed | Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer |
| title_short | Blood Microbiome Reveals the Impact of Lactobacillus on the Efficacy of Immunotherapy in Gastrointestinal Cancer |
| title_sort | blood microbiome reveals the impact of lactobacillus on the efficacy of immunotherapy in gastrointestinal cancer |
| topic | biomarker blood microbiome efficacy immunotherapy Lactobacillus |
| url | https://doi.org/10.1002/mco2.70316 |
| work_keys_str_mv | AT yashangzheng bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT wuhaolin bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT junquanchen bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT xiaoliwei bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT jiaqianhuang bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT yuhongxu bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT mengyang bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT qihuazhang bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT zhijunzuo bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT zhaoyingyang bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT panzhang bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT ngakihong bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT luxuanliu bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT zhaoleizeng bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT ruihuaxu bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer AT huiyanluo bloodmicrobiomerevealstheimpactoflactobacillusontheefficacyofimmunotherapyingastrointestinalcancer |